Ann. Oncol; 2024 Jun 26; EPub Ahead of Print; E Felip, BC Cho, V Gutiérrez, et al #Cancer Management #Lung #Nonsmall Cell Lung Cancer #Targeted/Biologic therapy Lancet; 2024 May 16; EPub Ahead of Print; CC Parker, NW Clarke, AD Cook, et al #Cancer Management #General Oncology #Prostate #Prostate Cancer Commentary by Oliver Sartor MD Lancet; 2024 Jun 1; 10442 (403)2416-2425; CC Parker, H Kynaston, AD Cook, et al #Cancer Management #General Oncology #Prostate #Prostate Cancer Commentary by Oliver Sartor MD N. Engl. J. Med; 2024 Jun 26; EPub Ahead of Print; BC Cho, S Lu, E Felip, et al #Cancer Management #Targeted/Biologic therapy Nat. Med.; 2024 Jun 6; EPub Ahead of Print; R Li, PH Shah, TF Stewart, et al #Bladder Cancer #Cancer Management #Genitourinary (Non-Prostate) #Targeted/Biologic therapy Commentary by Prof. Dr. Alexander van Akkooi MD, PhD Am. J. Hematol; 2024 Jun 6; EPub Ahead of Print; P Guglielmelli, B Mora, F Gesullo, et al #Hematology Commentary by Hannah Goulart MD & Sanam Loghavi MD Lancet Haematol; 2024 Jun 13; EPub Ahead of Print; KM Linton, U Vitolo, W Jurczak, et al #Cancer Management #General Oncology #Hematology #Lymphomas #Non-Hodgkin's Lymphoma N. Engl. J. Med; 2024 Jun 27; 390 (24)2284-2294; SR Plotkin, KH Yohay, PL Nghiemphu, et al #CNS/Brain Am. J. Hematol; 2024 Jun 17; EPub Ahead of Print; A Röth, G He, H Tong, et al #Hematology J. Clin. Oncol; 2024 Jun 10; EPub Ahead of Print; NB Leighl, H Akamatsu, SM Lim, et al #Lung J. Clin. Oncol; 2024 Jun 12; EPub Ahead of Print; C Antoniotti, D Rossini, F Pietrantonio, et al #Colon and Rectum

Tiragolumab Combo Does Not Reach Survival End Points in Nonsquamous NSCLC Developers intend to halt the phase 2/3 SKYSCRAPER-06 trial assessing tiragolumab plus atezolizumab and chemotherapy in nonsquamous NSCLC. GTB-3650 Snags FDA Clearance for IND Application in CD33+ Leukemia Investigators will assess the clinical activity, safety, and pharmacokinetics of GTB-3650 among those with CD33-expressing cancers in a phase 1 trial.
Videos Experts on multiple myeloma provide clinical insights on supportive care strategies for patients experiencing infections or secondary malignancies following CAR T-cell therapy.
Watch Now Key opinion leaders examine the application of tyrosine kinase inhibitors (TKIs) and evaluate first-line therapeutic approaches for renal cell carcinoma.
Watch Now Trending Findings from a phase 1 study may inform future trial designs intended to yield longer responses with PSCA-targeted CAR T cells.
  Acalabrutinib Appears More Effective in Earlier Lines of Treatment for CLL A pooled analysis trial assessed the impact of acalabrutinib in patients with chronic lymphocytic leukemia across treatment lines.